Joseph Schwartz

Kristen Kluska

Anupam Rama

Dennis Ding

Ritu Baral

Salveen Richter

Tazeen Ahmad

Dae Gon Ha

Eliana Merle

Gil Blum

Jeffrey Hung

Maxwell Skor

Ellie Merle

Joshua Fleishman

Mark Aleynick

Priyanka Grover

Tejas Wein

- Amicus Therapeutics reported strong Q2 global sales for its two commercial products: **Galafold** at over **$128 million**  **[1178879_tx_381235_0]**  (growing 10-15%  **[1178879_tx_381235_0]** ) and **Pombility AppFolda** at **$26 million**  **[1178879_tx_381235_0]**  (growing 50-65%  **[1178879_tx_381235_0]** ).
- The company is on track to achieve **GAAP profitability** for the first time in the second half of **2025**.  **[1178879_tx_381235_0]** 
- Amicus projects total revenue to exceed **$1 billion** within the next three years, with Galafold contributing approximately **60%** and Pombility AppFolda contributing **40%**.  **[1178879_tx_381235_4]** **[1178879_tx_381235_8]** 
- Amicus recently licensed **DMX-200**, a late Phase III asset for FSGS, a rare kidney disease with no approved treatments, which the company believes has the potential to be a **billion-dollar product** opportunity.  **[1178879_tx_381235_0]** **[1178879_tx_381235_4]** **[1178879_tx_381235_7]**  The Phase 3 study is **75% enrolled** and expects full enrollment by the end of **2025**, with final analysis in **2027**.  **[1178879_tx_381235_7]** **[1178879_tx_381235_6]**

Amicus Therapeutics Discusses Product Growth, New Pipeline Asset, and Path to Profitability

AMICUS THERAPEUTICS (FOLD)